Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Targeted delivery of a-galactosylceramide to CD8a+ dendritic cells optimizes type I NKT cell-based antitumor responses.

Macho-Fernandez E, Cruz LJ, Ghinnagow R, Fontaine J, Bialecki E, Frisch B, Trottein F, Faveeuw C. Targeted delivery of a-galactosylceramide to CD8a+ dendritic cells optimizes type I NKT cell-based antitumor responses. J Immunol. 2014 Jul 15; 193(2):961-9.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.